caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1760588693

Nizar TannirM.D.

PRACTICEMDACCSee all providers at this practice →
Medical OncologyHouston, TXI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Nizar Tannir's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 19 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER2021,856
NPI 104331692038231
Khaled Elsayes
Diagnostic Radiology · Houston, TX
2253
Kaveh Karimzad
Cardiology · Houston, TX
2059
RAVAL, BHARAT1863
Kara Thompson
Cardiology · Houston, TX
1852
William Murphy
Diagnostic Radiology · Houston, TX
1649
Elie Mouhayar
Cardiology · Houston, TX
1667
Raghunandan Vikram
Diagnostic Radiology · Houston, TX
1530
Leonardo Marcal
Diagnostic Radiology · Houston, TX
1555
Peter Kim
Cardiology · Houston, TX
1441
Juan Lopez-Mattei
Cardiology · Fort Myers, FL
1453
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
173
Unique beneficiaries
—
Total services
308
Distinct HCPCS
3
Medicare payment
$33K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 393 Medical Oncology providers in TX — bottom quintile (cohort median 4,999).
PRESCRIBING · PART D · 2024
Total Rx claims
331
Beneficiaries
—
Total drug cost
$3.9M
Distinct drugs
10
Brand share
63.4%
Top prescribed drugs
Lenvatinib Mesylate78 claims
Everolimus69 claims
Cabozantinib S-Malate49 claims
Nifedipine35 claims
Belzutifan24 claims
QUALITY · MIPS · 2024
Final MIPS score
84.3
Quality
70.8
Cost
67.6
Improvement activities
40.0
Promoting interop.
100.0
Payment adjustment
0.39%
Group
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
Total received
$23K
Payment records
87
By payment type
Travel and Lodging$12K
Consulting Fee$9K
Food and Beverage$3K
Education$136